Note from the advisory board

Dear Colleague,

Have you noticed that accelerating to Proof of Concept is more imperative than ever? We certainly have.

Ensuring you are up-to-date with the latest developments in early phase trials is critical to achieve PoC as quickly as possible and Phase I & IIa Clinical Trials provides the perfect opportunity to find out how.  Discover what your industry peers have been implementing in their early phase trials…

This year, our speakers will include more real-life examples than ever. They will share what they have been working on, what has gone wrong, and what has been learned.

Key for 2012, we have focused on ‘accelerating the journey to Proof of Concept’ and ‘Re-engineering the R&D process’ – we hope you’ll agree these are crucial topics to be investigated and discussed throughout the event.

We are very excited about the 2012 agenda and hope you will join us here in February.

Kind regards,

The Phase I & IIa Clinical Trials Advisory Board

• Clare Nott, Senior Clinical Project Manager
• Daren Austin, Head, Biopharm Clinical Pharmacology & Biometrics, GlaxoSmithKline
• David R. Jones, Expert Pharmaco-Toxicologist, MHRA
• James Dow, Director of Clinical Pharmacology & DMPK, Prosidion
• Mark Egerton, Managing Director, Quotient Bioresearch
• Sally Hughes, Senior Director, Clinical Pharmacology & Clinical Diagnostic Services, Eli Lilly
• Assem S. el Baghdady, Director, AlphaBeta Pharma
• Ian Wilding, President, Ian Wilding Associates